Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Nov 19 | 2019Sanofi Ends Sensile Medical Partnership; Onduo Parnters with Hidrate; Other Diabetes-Related NewsPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 19 | 2019Medtronic CY Q3 '19 (FY Q2 '20) Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring Nov 18 | 2019One Drop Showcases BG Prediction CapabilityPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other Nov 18 | 2019New Novo Partnership with Dicerna for RNAi TherapeuticsPurchase Blast$599
Posted in: SGLT2i Nov 16 | 2019Janssen Jumps Into Non-T2DM HF Arena With Innovative Invokana Trial Design (CHIEF-HF) To Rival BI/LLY and AZPurchase Blast$599
Posted in: Bolus Insulin Nov 15 | 2019New Ph1 LY900027 RAI Compound Could Be For Closed LoopPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Insulin Delivery, SGLT2i Nov 15 | 2019AZ's Qtrilmet Triple-combo Receives EC Approval; New Data from Fractyl, Dario, and ValeritasPurchase Blast$599
Posted in: Dual/triple agonist, Glucagon Nov 14 | 2019Zealand Q3 '19 Earnings Update; Ph2 dual agonist trial details revealedPurchase Blast$599
Posted in: Insulin Delivery, Other Nov 14 | 2019Livongo for Hypertension Demonstrates BP Benefit at 4 and 12 WeeksPurchase Blast$599
Posted in: SGLT2i Nov 13 | 2019Empa T1DM FDA Adcom Overwhelmingly Negative (2-14); Is SGLTi in T1DM Approvable in the US?Purchase Blast$599
Posted in: Bolus Insulin Nov 12 | 2019Oramed Oral Insulin (ORMD-0801) Ph2b T2DM Results UnclearPurchase Blast$599
Posted in: SGLT2i Nov 12 | 2019BI/Lilly Initiate Jardiance Acute HF Study (EMPULSE)Purchase Blast$599
Posted in: SGLT2i Nov 08 | 2019Empa T1DM Adcom Could Be Easier Than Sota, But Still Difficult; Briefing Documents AnalysisPurchase Blast$599
Posted in: Insulin Delivery Nov 08 | 2019Patient Dies on t:slim X2 with Basal IQ; Tandem Denies InvolvementPurchase Blast$599
Posted in: SGLT2i Nov 07 | 2019Lexicon Disputes Sota CRL with FDA; Lexicon and Xeris Q3 '19 Earnings Updates; Dexcom +30% TodayPurchase Blast$599
Posted in: Glucose Monitoring Nov 06 | 2019Dexcom and Livongo Q3 '19 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.